This message was sent to ##Email##
To advertise in this publication please click here
|
|
Advertisement
|
Log in to SLAS APPLIED and catch up on current topics of interest through conference and symposia recordings, webinars and podcasts. Recently released modules include the SLAS2020 Conference Recordings; SLAS Technology, SLAS Discovery; webinar recordings on data and materials augmentation platforms, and more.
ACCESS NOW
|
COVID-19 Scientists: We Want to Talk to You
SLAS
SLAS Scientific Director Mike Tarselli is looking for scientists who are working on the front lines to produce diagnostics, protective equipment, novel molecules, patient interventions or screening campaigns for existing therapies against SARS-CoV-2. If this is you or someone you know, send a single sentence about what you or this person is doing to help alleviate the pandemic to mtarselli@slas.org and he'll follow up directly with details on an upcoming feature in Electronic Laboratory Neighborhood.
|
|
Advertisement
Announcing the 2020 SLAS Building Biology in 3D Symposium
SLAS
SLAS is partnering with Scripps Research for the 2020 SLAS Building Biology in 3D Symposium (Jupiter, FL, USA). This two-day event will address the successes and limitations of using 3D systems in discovery and applied research, while also acknowledging the need for further exploration into what improvements can be made to ensure approaches can be more widely adopted. More specifically, topics will include current and near-future enabling technologies, applications of such systems in high-throughput screening, advances in imaging and analysis of data generated in these systems and the expansion into novel model systems. Save the date for November 17 – 18, 2020; Sponsorship and exhibit opportunities will be available.
LEARN MORE
|
|
New SLAS Discovery Call for Papers: Applications of Biophysics in Early Drug Discovery
SLAS
Just announced: a new SLAS Discovery Call for Papers, “Applications of Biophysics in Early Drug Discovery.”
Applications of Biophysics in Early Drug Discovery
Submission deadline: July 15
SLAS Discovery Guest Editors Geoffrey Holdgate, B.Sc. (AstraZeneca) and Christian Bergsdorf, Ph.D. (Novartis) invite the submission of manuscript proposals (abstracts) that describe impactful current and developing biophysical methods, biophysical screening and characterization, and related analyses and interpretation of biophysical results for an upcoming 2021 special issue.
VIEW COMPLETE SUBMISSION DETAILS
|
|
|
|
 |
|
The coronavirus (COVID-19) is a rapidly evolving threat, and the synthetic DNA that can help discover a vaccine and treatment is needed now — not in eight to ten weeks. SGI-DNA is supporting front-line researchers in combating the spread of COVID-19 by offering $50,000 in co-funding for the BioXp™ 3200 system.
|
|
SLAS APPLIED Featured Module of the Week: The Materials of Tomorrow, Today
SLAS
In his February webinar, “The Materials of Tomorrow, Today,” Alan Aspuru-Guzik (University of Toronto) explains his “materials acceleration platforms” (MAPs), that enable the combination of AI, high-throughput quantum chemistry (HTQC), and robotics to produce more complex screening approaches. This 48-minute, in-depth module is available for only $10 for SLAS Premier and Corporate Members or $30 for SLAS Networking Members and non-members.
DOWNLOAD TODAY
|
|
 |
|
Promoted by
Thermo Scientific
The Thermo Scientific™ Orbitor™ RS2 microplate mover is a collaborative bench-top mover that provides unbeatable reliability and improved process efficiency. It’s innovative bi-directional telescoping arm coupled with it’s expansive 360° workspace provide exceptional reach and precision, making the Orbitor RS2 your trusted laboratory productivity partner.
|
|
Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development
Genetic Engineering & Biotechnology News
While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader menu of therapeutic options.
In all, the tally of vaccines and treatments in development against COVID-19 as of April 13 was at least 161 candidates—more than double the 60 candidates highlighted in GEN's previous A-List summarizing therapies in the works against SARS-CoV-2.
|
|
Hydration, Solvation, and Isomerization of Methylglyoxal at the Air/Water Interface: New Mechanistic Pathways
Journal of the American Chemical Society
Aqueous-phase processing of methylglyoxal (MG) has been suggested to play a key role in the formation of secondary organic aerosols and catalyze particle growth in the atmosphere. However, the details of these processes remain speculative owing to the lack of a complete description of the physicochemical behavior of MG on atmospheric aerosols. Here, the solvation and hydrolysis of MG at the air/liquid water interface is studied via classical and first-principles molecular dynamics simulations combined with free-energy methods.
|
|
Super-Charging Drug Development for COVID-19
Science Daily
Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS's close genetic cousin, the novel coronavirus (COVID-19).
Led by Northwestern University and ShanghaiTech University, the team has produced the promising molecule, called valinomycin, in a cell-free system. With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.
|
|
Symptoms in ALS Mouse Model Improve With CRISPR Base Editing
The Scientist
Base editors, which convert one nucleotide to another without a double-strand DNA break, have the potential to treat diseases caused by mutant genes. One drawback, though, is that the DNA that encodes CRISPR base editors is long—too long to fit in the adeno-associated viruses (AAVs) most commonly used for gene therapy. In a study published in Molecular Therapy on January 13, researchers split the DNA encoding a base editor into two AAV vectors and injected them into a mouse model of inherited amyotrophic lateral sclerosis (ALS).
|
|
A New Generation of Antibody-Drug Conjugates for Cancer Patients
Chemical & Engineering News
After a decade-long trickle of antibody-drug conjugates (ADCs), the U.S. Food and Drug Administration in 2019 approved three new ADCs to treat various cancers. That burst of activity brought the total number of FDA-approved ADCs on the market to seven, a definite uptick to end the decade.
ADCs are antibodies connected to cell-killing, small-molecule payloads via chemical linkers. To fight cancer, the antibodies hook up to proteins on the surfaces of tumor cells. Once the ADCs are there, the tumor cells engulf the ADCs; rip up the linkers via chemical, enzymatic, or biological processes; and release the small-molecule payloads. The payloads then kill the tumor cells.
|
|
'Freeze Frame' Chemistry to Unlock Drugs of the Future
Phys.org
Researchers are taking snapshots of chemical reactions in a trillionth of a second in the hope of developing the next generation of antibiotics and anti-viral drugs.
Using state-of-the-art laser technology, scientists at Cardiff University and the Rosalind Franklin Institute are creating "freeze frame movies" of chemical reactions, with a starring role for a specific enzyme that could be used to make new drugs that are active against viruses, such as COVID-19.
|
|
A Technique for Biomanufacturing Medicines during Space Flights
Lab Manager
An instrument currently aboard the International Space Station could grow E. coli bacteria in space, opening a new path to biomanufacturing drugs during long term space flights. Research published April 10 in Nature Microgravity used an Earth-bound simulator of the space station instrument to grow E. coli, demonstrating that it can be nurtured with methods that promise to be more suitable for space travel than existing alternatives.
"If we can get microorganisms to grow well in space, astronauts can use them to make pharmaceuticals on demand," said Richard Bonocora, senior author and a faculty member in the Department of Biological Sciences at Rensselaer Polytechnic Institute.
|
|
Artificial Intelligence Is Evolving All by Itself
Science Magazine
Artificial intelligence (AI) is evolving—literally. Researchers have created software that borrows concepts from Darwinian evolution, including “survival of the fittest,” to build AI programs that improve generation after generation without human input. The program replicated decades of AI research in a matter of days, and its designers think that one day, it could discover new approaches to AI.
“While most people were taking baby steps, they took a giant leap into the unknown,” says Risto Miikkulainen, a computer scientist at the University of Texas, Austin, who was not involved with the work.
|
|
Job Seekers: Post your résumé and sign up for new job alerts by keyword.
Employers: Search résumés, post an open position, internship or post-doc opportunity. SLAS Premier and Corporate Members get a discount on all new job postings.
Research Specialist
University of Pittsburgh
US – PA - Pittsburgh
Postdoctoral Research Associate
Rice University
US – Houston – Texas
Postdoctoral Scholar
Lawrence Berkeley National Laboratory
US – CA – Berkeley
Search Jobs at SLAS Career Connections
| . |
| THANK YOU |
|
2020 SLAS CORPORATE MEMBERS |
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
